Considering the affinity of antipsychotics and antidepressants for 5-HT6 receptors and the wide distribution of 5-HT6 receptors in the brain regions implicated for the control of mood and behavior, 5-HT6 agents are candidates for use in the treatment of NPS of AD. This evidence concerns the gene HTR6 and Alzheimer disease.